← All trials
NCT04879615
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 21, 2021
- Primary completion
- May 31, 2023
- Completion date
- Dec 31, 2023
- First posted
- May 10, 2021
- Last posted
- Jul 16, 2021
- Enrollment
- 372
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Zhejiang UniversityLead sponsor
- Shaoxing People's HospitalCollaborator
- Lishui Country People's HospitalCollaborator
- Zhoushan People's HospitalCollaborator
- Zhejiang UniversityCollaborator
- Huzhou UniversityCollaborator
- Jiaxing People's HospitalCollaborator
- Jiaxing Second HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.